Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Beta blockers Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 Nonselective Agents
  • 1.3.3 Selective Agents
• 1.4 Market Segment by Application
  • 1.4.1 Global Beta blockers Market Share by Application (2019-2025)
  • 1.4.2 Abnormal Heart Rhythms
  • 1.4.3 Hypertension
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Beta blockers Market Size
  • 2.1.1 Global Beta blockers Revenue 2014-2025
  • 2.1.2 Global Beta blockers Sales 2014-2025
• 2.2 Beta blockers Growth Rate by Regions
  • 2.2.1 Global Beta blockers Sales by Regions 2014-2019
  • 2.2.2 Global Beta blockers Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Beta blockers Sales by Manufacturers
  • 3.1.1 Beta blockers Sales by Manufacturers 2014-2019
  • 3.1.2 Beta blockers Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 Beta blockers Revenue by Manufacturers (2014-2019)
  • 3.2.2 Beta blockers Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Beta blockers Market Concentration Ratio (CR5 and HHI)
• 3.3 Beta blockers Price by Manufacturers
• 3.4 Key Manufacturers Beta blockers Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Beta blockers Market
• 3.6 Key Manufacturers Beta blockers Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 Nonselective Agents Sales and Revenue (2014-2019)
  • 4.1.2 Selective Agents Sales and Revenue (2014-2019)
• 4.2 Global Beta blockers Sales Market Share by Type
• 4.3 Global Beta blockers Revenue Market Share by Type
• 4.4 Beta blockers Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Beta blockers Sales by Application

6 United States

• 6.1 United States Beta blockers Breakdown Data by Company
• 6.2 United States Beta blockers Breakdown Data by Type
• 6.3 United States Beta blockers Breakdown Data by Application

7 European Union

• 7.1 European Union Beta blockers Breakdown Data by Company
• 7.2 European Union Beta blockers Breakdown Data by Type
• 7.3 European Union Beta blockers Breakdown Data by Application

8 China

• 8.1 China Beta blockers Breakdown Data by Company
• 8.2 China Beta blockers Breakdown Data by Type
• 8.3 China Beta blockers Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World Beta blockers Breakdown Data by Company
• 9.2 Rest of World Beta blockers Breakdown Data by Type
• 9.3 Rest of World Beta blockers Breakdown Data by Application
• 9.4 Rest of World Beta blockers Breakdown Data by Countries
  • 9.4.1 Rest of World Beta blockers Sales by Countries
  • 9.4.2 Rest of World Beta blockers Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 Pfizer
  • 10.1.1 Pfizer Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of Beta blockers
  • 10.1.4 Beta blockers Product Introduction
  • 10.1.5 Pfizer Recent Development
• 10.2 Novartis
  • 10.2.1 Novartis Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of Beta blockers
  • 10.2.4 Beta blockers Product Introduction
  • 10.2.5 Novartis Recent Development
• 10.3 Merck
  • 10.3.1 Merck Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of Beta blockers
  • 10.3.4 Beta blockers Product Introduction
  • 10.3.5 Merck Recent Development
• 10.4 Astra Zeneca
  • 10.4.1 Astra Zeneca Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of Beta blockers
  • 10.4.4 Beta blockers Product Introduction
  • 10.4.5 Astra Zeneca Recent Development
• 10.5 Jhonson and Johnson
  • 10.5.1 Jhonson and Johnson Company Details
  • 10.5.2 Company Description and Business Overview
  • 10.5.3 Sales, Revenue and Market Share of Beta blockers
  • 10.5.4 Beta blockers Product Introduction
  • 10.5.5 Jhonson and Johnson Recent Development
• 10.6 Eli Lilly
  • 10.6.1 Eli Lilly Company Details
  • 10.6.2 Company Description and Business Overview
  • 10.6.3 Sales, Revenue and Market Share of Beta blockers
  • 10.6.4 Beta blockers Product Introduction
  • 10.6.5 Eli Lilly Recent Development
• 10.7 Sanofi
  • 10.7.1 Sanofi Company Details
  • 10.7.2 Company Description and Business Overview
  • 10.7.3 Sales, Revenue and Market Share of Beta blockers
  • 10.7.4 Beta blockers Product Introduction
  • 10.7.5 Sanofi Recent Development
• 10.8 Bristol-Myers Squibb
  • 10.8.1 Bristol-Myers Squibb Company Details
  • 10.8.2 Company Description and Business Overview
  • 10.8.3 Sales, Revenue and Market Share of Beta blockers
  • 10.8.4 Beta blockers Product Introduction
  • 10.8.5 Bristol-Myers Squibb Recent Development
• 10.9 Bayer
  • 10.9.1 Bayer Company Details
  • 10.9.2 Company Description and Business Overview
  • 10.9.3 Sales, Revenue and Market Share of Beta blockers
  • 10.9.4 Beta blockers Product Introduction
  • 10.9.5 Bayer Recent Development
• 10.10 GSK
  • 10.10.1 GSK Company Details
  • 10.10.2 Company Description and Business Overview
  • 10.10.3 Sales, Revenue and Market Share of Beta blockers
  • 10.10.4 Beta blockers Product Introduction
  • 10.10.5 GSK Recent Development
• 10.11 Teva Pharmaceutical

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 Beta blockers Sales Channels
  • 11.2.2 Beta blockers Distributors
• 11.3 Beta blockers Customers

12 Market Forecast

• 12.1 Global Beta blockers Sales and Revenue Forecast 2019-2025
• 12.2 Global Beta blockers Sales Forecast by Type
• 12.3 Global Beta blockers Sales Forecast by Application
• 12.4 Beta blockers Forecast by Regions
  • 12.4.1 Global Beta blockers Sales Forecast by Regions 2019-2025
  • 12.4.2 Global Beta blockers Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details

Beta blockers, also written β-blockers, are a class of medications that are predominantly used to manage abnormal heart rhythms, and to protect the heart from a second heart attack (myocardial infarction) after a first heart attack (secondary prevention). They are also widely used to treat high blood pressure (hypertension), although they are no longer the first choice for initial treatment of most patients.
In 2019, the market size of Beta blockers is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Beta blockers.

This report studies the global market size of Beta blockers, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Beta blockers sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Pfizer
Novartis
Merck
Astra Zeneca
Jhonson and Johnson
Eli Lilly
Sanofi
Bristol-Myers Squibb
Bayer
GSK
Teva Pharmaceutical

Market Segment by Product Type
Nonselective Agents
Selective Agents

Market Segment by Application
Abnormal Heart Rhythms
Hypertension

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Beta blockers status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Beta blockers manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Beta blockers are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025